Navigation Links
MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Date:10/1/2007

also delighted the drug appeared so effective by a simple subconjunctival injection, a route of administration that is able to decrease the risk and treatment burden to patients and physicians alike. As a result, we can confidently proceed with our clinical development of sirolimus as a product delivered via subconjunctival injection."

With regard to safety and tolerability, the study showed no evidence of increased intraocular pressure or inflammatory response to treatment. MacuSight intends to complete its collection and analysis of all data from this trial and present final findings later this year.

"From a patient treatment standpoint, the study findings related to the safety and biological activity of sirolimus administered through subconjunctival injection are very exciting," stated Pravin U. Dugel, M.D., clinical instructor, vitreoretinal diseases and surgery, department of ophthalmology, University of Arizona, partner at Retinal Consultants of Arizona in Phoenix, Arizona, and the study's lead investigator. "By offering both physicians and patients significant benefits in the way of reduced invasiveness, safety and ease of administration, the subconjunctival injection has the potential to dramatically improve the current DME treatment paradigm."

Additionally, MacuSight has completed enrollment of its second Phase 1 trial which is examining its same proprietary sirolimus formulation in patients with exudative age-related macular degeneration. Results from this second trial are expected to be presented during the first half of 2008.

About Sirolimus

Sirolimus, originally known as rapamycin, is a highly-potent, broad-acting compound that has demonstrated the ability to combat disease through multiple mechanisms of action including immunosuppressive, anti-angiogenic, anti-migratory, anti-proliferative, anti-fibrotic and anti-permeability activity. Based on the versatility associated with these multiple mechanisms of action, MacuSight
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... ANDOVER, Mass. , July 24, 2014   ... pulmonary function testing (PFT) employing precise ultrasound technology, announced ... as the instrument to measure Carbon Monoxide Diffusing Capacity ... Study, the most comprehensive study of Chronic Obstructive Pulmonary ... leading cause of death in the U.S. and affects ...
(Date:7/24/2014)... and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) announced today that the ... on Thursday, August 7, 2014, and that the Company ... 4:30 p.m. ET that afternoon. Management will provide an ... a general business update. To access ...
(Date:7/23/2014)... Australia , July 24, 2014 ... Melbourne , the agreement seeks to increase access ... At the AIDS 2014 conference in ... a new licensing agreement with Gilead Sciences for tenofovir alafenamide ... The licence will allow manufacturers in India ...
Breaking Medicine Technology:EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 3
... Medical has been at the cutting edge of ... famous Resusci Anne in 1960. Fifty years on, ... launches its latest SimMan patient simulator, SimMan® Essential. ... (Photo: http://www.newscom.com/cgi-bin/prnh/20100830/NY56743 ) ...
... accelerating pace of scientific discovery in life sciences, coupled ... of genetic information, the field of personalized medicine has ... predictive and preventative care utilizing diagnostics that allow physicians ... therapeutic regimes are most effective, and determine long-term susceptibility ...
Cached Medicine Technology:Laerdal Introduces SimMan Essential 2Laerdal Introduces SimMan Essential 3Personalized Medicine: Conference Provides Update on Progress and Prospects 2
(Date:7/24/2014)... babies are at risk for autism because they have an ... ways to detect Autism Spectrum Disorder (ASD) earlier in life, ... and how they relate to the possibility and severity of ... the connection between early joint attention before one year and ... communication that develops toward the end of the first year. ...
(Date:7/24/2014)... 2014 Skirt Sports, the innovative women’s running ... the running skirt. Born from an idea by professional triathlete ... Ironman race in 2004, this one innovative piece of running ... money from her victory in Wisconsin to incorporate Skirt Sports, ... athletic skirts. , “When I drew the first sketch of ...
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & Modifiers ... Poultry, Cattle, Pets, Aquaculture, and Others) - Global Trends ... palatability enhancers & modifiers market with an analysis and ... of types of feed flavors, sweeteners, and text rants. ... spread through 275 pages and in-depth TOC on "Feed ...
(Date:7/24/2014)... high school students are smoking tobacco products at the ... new data from the Prevention Research Center for Healthy ... more than 22 percent, or one in five high ... the prior 30 days. , Equally surprising is that ... or water pipes, more than cigarettes matching a ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July ... publicly funded insurance program for the poor, visit the emergency ... privately insured youngsters, a U.S. survey finds. And kids ... to visit for a reason other than a serious medical ... Centers for Disease Control and Prevention. Reliance ...
Breaking Medicine News(10 mins):Health News:Early warning sign for babies at risk of autism 2Health News:Skirt Sports Celebrates Its 10-Year Anniversary and 10 Years of the Running Skirt With a Virtual Community Building Run 2Health News:Skirt Sports Celebrates Its 10-Year Anniversary and 10 Years of the Running Skirt With a Virtual Community Building Run 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4Health News:Cuyahoga County high school students smoking at the same rate as adults 2Health News:Cuyahoga County high school students smoking at the same rate as adults 3Health News:Cuyahoga County high school students smoking at the same rate as adults 4Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 2Health News:Many Kids With Medicaid Use ER as Doctor's Office: CDC 3
... ongoing decline in the cancer death rate in the ... receive care that addresses the psychological and social problems ... psychological, emotional, and social side effects can increase patients, ... treatment. CANCER CARE FOR THE WHOLE PATIENT: MEETING ...
... October 16, 2007 -- Reducing the number of ... be more cost-effective than most public health and ... at Columbia University Mailman School of Public Health ... that class-size reductions would generate more quality-adjusted life-year ...
... 16 Expected to be,her family,s Halloween treat, Catharine ... pound, 10 ounces. Today, the five-year-old of,Allentown, Pennsylvania has ... who was born 16 weeks early, measuring only 12,inches ... half a million,babies born preterm each year in the ...
... (US Food Sources Preferred Over Imports), FRESNO, Calif., ... surveyed say their confidence in the food supply has,decreased ... conducted by,the California Olive Industry. The registered dieticians ... with 66% saying that when presented with a,choice, they ...
... NASHVILLE, Tenn., Oct. 16 HCA today announced the,appointment ... West Division,which is based in Las Vegas, effective Jan. ... retirement. As Far West Division President, Rogers will ... currently include nine,hospitals and seven ambulatory surgery centers with ...
... The Evening Will Feature Special Performances by John Legend, Joss Stone, ... ... The G&P Foundation for Cancer,Research will honor four outstanding individuals at ... Chief,Executive Officer of BET Networks Debra L. Lee, Chief Hematologic Oncology,Memorial ...
Cached Medicine News:Health News:Study shows reducing class size may be more cost-effective than most medical interventions 2Health News:March of Dimes Selects Pennsylvania Girl as 2008 National Ambassador 2Health News:Dieticians & Nutritionists Report Decreased Confidence in Food Supply 2Health News:Bryan R. Rogers Appointed President of Far West Division 2Health News:The G&P Foundation Celebrates 10 Years of Funding Life Saving Research at The 2007 Angel Ball Honoring Glenda Bailey, Debra L. Lee, Dr. Stephen D. Nimer and the Late H.H. Sheik Zayed Bin Sultan Al Nahyan 2Health News:The G&P Foundation Celebrates 10 Years of Funding Life Saving Research at The 2007 Angel Ball Honoring Glenda Bailey, Debra L. Lee, Dr. Stephen D. Nimer and the Late H.H. Sheik Zayed Bin Sultan Al Nahyan 3Health News:The G&P Foundation Celebrates 10 Years of Funding Life Saving Research at The 2007 Angel Ball Honoring Glenda Bailey, Debra L. Lee, Dr. Stephen D. Nimer and the Late H.H. Sheik Zayed Bin Sultan Al Nahyan 4Health News:The G&P Foundation Celebrates 10 Years of Funding Life Saving Research at The 2007 Angel Ball Honoring Glenda Bailey, Debra L. Lee, Dr. Stephen D. Nimer and the Late H.H. Sheik Zayed Bin Sultan Al Nahyan 5
Raysoft Foldable Intraocular Lens....
XL OCTO Hydrophilic Acrylic Lens....
... The Collamer™ lens, model CQ2003V, combines the ... design. This lens contains a Collamer optic ... no angulation. These loops offer flexibility comparable ... tensile strength, and superior "shape memory". The ...
Biocryl™ Acrylic Foldable Lens....
Medicine Products: